Nordea Investment Management AB Raises Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Nordea Investment Management AB boosted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 22.5% during the 4th quarter, Holdings Channel reports. The firm owned 282,834 shares of the company’s stock after acquiring an additional 52,031 shares during the period. Nordea Investment Management AB’s holdings in Roivant Sciences were worth $3,306,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Everence Capital Management Inc. purchased a new position in shares of Roivant Sciences in the 4th quarter worth about $162,000. GAMMA Investing LLC raised its position in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares during the period. JPMorgan Chase & Co. raised its position in Roivant Sciences by 4.4% in the third quarter. JPMorgan Chase & Co. now owns 822,582 shares of the company’s stock worth $9,493,000 after acquiring an additional 34,453 shares during the period. Retirement Systems of Alabama boosted its stake in Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after acquiring an additional 112,286 shares during the last quarter. Finally, Tyro Capital Management LLC grew its position in shares of Roivant Sciences by 0.6% during the 3rd quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company’s stock valued at $20,252,000 after acquiring an additional 10,649 shares during the period. Institutional investors own 64.76% of the company’s stock.

Insider Activity

In other news, CIO Mayukh Sukhatme sold 185,946 shares of the stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $12.00, for a total value of $2,231,352.00. Following the sale, the executive now directly owns 18,836,547 shares of the company’s stock, valued at approximately $226,038,564. This represents a 0.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the transaction, the chief operating officer now directly owns 617,470 shares of the company’s stock, valued at approximately $7,193,525.50. This represents a 13.94 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,942,629 shares of company stock worth $23,071,486. 7.90% of the stock is owned by corporate insiders.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $10.63 on Friday. The stock has a market capitalization of $7.74 billion, a price-to-earnings ratio of 1.88 and a beta of 1.27. The company’s fifty day simple moving average is $11.88 and its two-hundred day simple moving average is $11.58. Roivant Sciences Ltd. has a 1 year low of $9.69 and a 1 year high of $13.06.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ROIV. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.93.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.